The entry of new drugs in the macular degeneration treatment market made little impact on Eylea’s sales. Eylea continued to top the macular degeneration treatment market last year, posting sales of KRW 96.7 billion. The Eylea biosimilars Vabysmo and Lucentis, which were released last year, have shown little presence in the market yet.

According to the market research institution IQVIA on Thursday, Eylea’s revenue last year was KRW 96.7 billion, up 20.2% from the KRW 80.4 billion it had made in 2022.

Eylea is a vascular endothelial growth factor-A (VEGF-A) inhibitor for macular degeneration that was developed by Bayer and Regeneron. The drug was approved in Korea in 2013 and en